Aktuellt
SENASTE
We expect Q1/23 sales of SEK 21m, y/y growth of 200% from a pandemic-affected quarter last year. Both Cranial PSI and Catalyst should do well on the back of some recent positive news and signs of elective care gradually improving. We increase our Q1/22 sales estimate by SEK ~2m as we expect Cranial to perform well in Germany and France, boosting EU sales. We reiterate our DCF-based mid-point of SEK 11 per share.
LÄS MER
